Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.

Newton CL, Wood MD, Strange PG.

PLoS One. 2016 Jul 5;11(7):e0158808. doi: 10.1371/journal.pone.0158808. eCollection 2016.

2.

CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, Ross RA.

Mol Pharmacol. 2013 Feb;83(2):322-38. doi: 10.1124/mol.112.080879. Epub 2012 Nov 15.

3.

Purification of the human G protein-coupled receptor adenosine A(2a)R in a stable and functional form expressed in Pichia pastoris.

Singh S, Zhang M, Bertheleme N, Strange PG, Byrne B.

Curr Protoc Protein Sci. 2012 Feb;Chapter 29:Unit 29.4. doi: 10.1002/0471140864.ps2904s67.

PMID:
22294329
4.

Radioligand binding analysis as a tool for quality control of GPCR production for structural characterization: adenosine A(2a)R as a template for study.

Singh S, Zhang M, Bertheleme N, Kara E, Strange PG, Byrne B.

Curr Protoc Protein Sci. 2012 Feb;Chapter 29:Unit 29.3. doi: 10.1002/0471140864.ps2903s67.

PMID:
22294328
5.

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Kara E, Lin H, Svensson K, Johansson AM, Strange PG.

Br J Pharmacol. 2010 Nov;161(6):1343-50. doi: 10.1111/j.1476-5381.2010.01010.x.

6.

Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Strange PG.

Br J Pharmacol. 2010 Nov;161(6):1238-49. doi: 10.1111/j.1476-5381.2010.00963.x. Review.

7.

A purified C-terminally truncated human adenosine A(2A) receptor construct is functionally stable and degradation resistant.

Singh S, Hedley D, Kara E, Gras A, Iwata S, Ruprecht J, Strange PG, Byrne B.

Protein Expr Purif. 2010 Nov;74(1):80-7. doi: 10.1016/j.pep.2010.04.018. Epub 2010 May 11.

PMID:
20438843
8.

Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.

Kara E, Lin H, Strange PG.

J Neurochem. 2010 Mar;112(6):1442-53. doi: 10.1111/j.1471-4159.2009.06554.x. Epub 2009 Dec 24.

9.

Modelling the interdependence between the stoichiometry of receptor oligomerization and ligand binding for a coexisting dimer/tetramer receptor system.

Rovira X, Vivó M, Serra J, Roche D, Strange PG, Giraldo J.

Br J Pharmacol. 2009 Jan;156(1):28-35. doi: 10.1111/j.1476-5381.2008.00031.x. Review.

10.

Large-scale functional expression of WT and truncated human adenosine A2A receptor in Pichia pastoris bioreactor cultures.

Singh S, Gras A, Fiez-Vandal C, Ruprecht J, Rana R, Martinez M, Strange PG, Wagner R, Byrne B.

Microb Cell Fact. 2008 Oct 10;7:28. doi: 10.1186/1475-2859-7-28.

11.

Antipsychotic drug action: antagonism, inverse agonism or partial agonism.

Strange PG.

Trends Pharmacol Sci. 2008 Jun;29(6):314-21. doi: 10.1016/j.tips.2008.03.009. Epub 2008 May 28. Review.

PMID:
18471899
12.

Signaling mechanisms of GPCR ligands.

Strange PG.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):196-202. Review.

PMID:
18283607
13.

Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Strange PG.

Br J Pharmacol. 2008 Apr;153(7):1353-63. doi: 10.1038/sj.bjp.0707672. Epub 2008 Jan 28. Review.

14.

Allosteric effects of antagonists on signalling by the chemokine receptor CCR5.

Haworth B, Lin H, Fidock M, Dorr P, Strange PG.

Biochem Pharmacol. 2007 Sep 15;74(6):891-7. Epub 2007 Jun 26.

PMID:
17669370
15.

Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.

Leach K, Charlton SJ, Strange PG.

Biochem Pharmacol. 2007 Sep 15;74(6):881-90. Epub 2007 Jun 20.

PMID:
17645873
16.

Mechanisms underlying agonist efficacy.

Strange PG.

Biochem Soc Trans. 2007 Aug;35(Pt 4):733-6. Review.

PMID:
17635136
17.
18.

Agonist-dependent internalization of D2 receptors: Imaging quantification by confocal microscopy.

Goggi JL, Sardini A, Egerton A, Strange PG, Grasby PM.

Synapse. 2007 Apr;61(4):231-41.

PMID:
17230553
19.

Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Lin H, Saisch SG, Strange PG.

Br J Pharmacol. 2006 Oct;149(3):291-9. Epub 2006 Aug 21.

20.

Diverse signalling by different chemokines through the chemokine receptor CCR5.

Mueller A, Mahmoud NG, Strange PG.

Biochem Pharmacol. 2006 Sep 14;72(6):739-48. Epub 2006 Jul 17.

PMID:
16844091
21.

Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor.

Vivo M, Lin H, Strange PG.

Mol Pharmacol. 2006 Jan;69(1):226-35. Epub 2005 Oct 4.

PMID:
16204468
22.

Oligomers of D2 dopamine receptors: evidence from ligand binding.

Strange PG.

J Mol Neurosci. 2005;26(2-3):155-60. Review.

PMID:
16012188
23.

Mechanisms of inverse agonist action at D2 dopamine receptors.

Roberts DJ, Strange PG.

Br J Pharmacol. 2005 May;145(1):34-42.

24.

The influence of G protein subtype on agonist action at D2 dopamine receptors.

Nickolls SA, Strange PG.

Neuropharmacology. 2004 Nov;47(6):860-72.

PMID:
15527820
25.

Mechanisms of agonist action at D2 dopamine receptors.

Roberts DJ, Lin H, Strange PG.

Mol Pharmacol. 2004 Dec;66(6):1573-9. Epub 2004 Aug 31.

PMID:
15340043
26.
27.

Domain swapping in the human histamine H1 receptor.

Bakker RA, Dees G, Carrillo JJ, Booth RG, López-Gimenez JF, Milligan G, Strange PG, Leurs R.

J Pharmacol Exp Ther. 2004 Oct;311(1):131-8. Epub 2004 May 24.

PMID:
15159444
28.

Inverse agonist properties of atypical antipsychotic drugs.

Akam E, Strange PG.

Biochem Pharmacol. 2004 Jun 1;67(11):2039-45.

PMID:
15135301
29.

Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.

Roberts DJ, Lin H, Strange PG.

Biochem Pharmacol. 2004 May 1;67(9):1657-65.

PMID:
15081865
30.

Mechanisms of internalization and recycling of the chemokine receptor, CCR5.

Mueller A, Strange PG.

Eur J Biochem. 2004 Jan;271(2):243-52.

31.

The chemokine receptor, CCR5.

Mueller A, Strange PG.

Int J Biochem Cell Biol. 2004 Jan;36(1):35-8. Review.

PMID:
14592532
33.

Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells.

Gazi L, Wurch T, Lopéz-Giménez JF, Pauwels PJ, Strange PG.

FEBS Lett. 2003 Jun 19;545(2-3):155-60.

34.

Characterization of the endokinins: human tachykinins with cardiovascular activity.

Page NM, Bell NJ, Gardiner SM, Manyonda IT, Brayley KJ, Strange PG, Lowry PJ.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6245-50. Epub 2003 Apr 25.

36.

Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity.

Nickolls SA, Strange PG.

Biochem Pharmacol. 2003 Apr 1;65(7):1139-50.

PMID:
12663049
38.

Formation of oligomers by G protein-coupled receptors.

Gazi L, López-Giménez JF, Strange PG.

Curr Opin Drug Discov Devel. 2002 Sep;5(5):756-63. Review.

PMID:
12630296
39.

Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor.

Payne SL, Johansson AM, Strange PG.

J Neurochem. 2002 Sep;82(5):1106-17.

40.

Pharmacological characterization of the chemokine receptor, CCR5.

Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG.

Br J Pharmacol. 2002 Feb;135(4):1033-43.

41.

Mechanisms of inverse agonism at G-protein-coupled receptors.

Strange PG.

Trends Pharmacol Sci. 2002 Feb;23(2):89-95. Review.

PMID:
11830266
42.

Pathways for internalization and recycling of the chemokine receptor CCR5.

Mueller A, Kelly E, Strange PG.

Blood. 2002 Feb 1;99(3):785-91.

PMID:
11806977
43.

Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype.

Cordeaux Y, Nickolls SA, Flood LA, Graber SG, Strange PG.

J Biol Chem. 2001 Aug 3;276(31):28667-75. Epub 2001 May 21.

45.

Dopamine D2 receptor dimer formation: evidence from ligand binding.

Armstrong D, Strange PG.

J Biol Chem. 2001 Jun 22;276(25):22621-9. Epub 2001 Feb 23.

46.
48.

Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues.

Hoare SR, Coldwell MC, Armstrong D, Strange PG.

Br J Pharmacol. 2000 Jul;130(5):1045-59.

49.

Agonist binding to G-protein coupled receptors.

Strange PG.

Br J Pharmacol. 2000 Feb;129(4):820-1. No abstract available.

50.

Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding.

Coley C, Woodward R, Johansson AM, Strange PG, Naylor LH.

J Neurochem. 2000 Jan;74(1):358-66.

Supplemental Content

Loading ...
Support Center